Recombinant RUNX3 Monoclonal Antibody (AN301806L)
For research use only.
| Verified Samples |
Verified Samples in WB: MCF-7(Negative control), Ramos, Raji, HT-1080 Verified Samples in IP: Raji cells extracts |
| Dilution | WB 1:500-1:1000, IP 1:25-1:50 |
| Isotype | IgG, κ |
| Host | Rabbit |
| Reactivity | Human, |
| Applications | WB, IP |
| Clonality | Monoclonal;Recombinant |
| Immunogen | Recombinant human RUNX3 fragment |
| Abbre | RUNX3 |
| Synonyms | AML, RUNX, CBFA, Oncogene AML, Core-binding factor subunit alpha, Runt-related transcription factor, PEBP2A, RUNX3, AML2, CBFA3, PEBP2aC, Acute myeloid leukemia 2 protein, Core-binding factor subunit alpha-3, Oncogene AML-2, Runt-related transcription factor 3, PEBP2A3 |
| Swissprot | |
| Calculated MW | 46 kDa |
| Observed MW |
44-46 kDa
The actual band is not consistent with the expectation.
Western blotting is a method for detecting a certain protein in a complex sample based on the specific binding of antigen and antibody. Different proteins can be divided into bands based on different mobility rates. The mobility is affected by many factors, which may cause the observed band size to be inconsistent with the expected size. The common factors include: 1. Post-translational modifications: For example, modifications such as glycosylation, phosphorylation, methylation, and acetylation will increase the molecular weight of the protein. 2. Splicing variants: Different expression patterns of various mRNA splicing bodies may produce proteins of different sizes. 3. Post-translational cleavage: Many proteins are first synthesized into precursor proteins and then cleaved to form active forms, such as COL1A1. 4. Relative charge: the composition of amino acids (the proportion of charged amino acids and uncharged amino acids). 5. Formation of multimers: For example, in protein dimer, strong interactions between proteins can cause the bands to be larger. However, the use of reducing conditions can usually avoid the formation of multimers. If a protein in a sample has different modified forms at the same time, multiple bands may be detected on the membrane. |
| Cellular Localization | Nucleus, Cytoplasm |
| Concentration | 1 mg/mL |
| Buffer | PBS, 50% glycerol, 0.05% Proclin 300, 0.05% protein protectant. |
| Purification Method | Protein A purified |
| Research Areas | Epigenetics and Nuclear Signaling, Neuroscience, Stem Cells, Cancer, Developmental Biology |
| Clone No. | A518 |
| Conjugation | Unconjugated |
| Storage | Store at -20°C Valid for 12 months. Avoid freeze / thaw cycles. |
| Shipping | Ice bag |
| background | RUNX3 is a member of the Runt family of transcription factors, playing an important role in the suppression of gastric epithelium cell proliferation, dorsal root ganglia neurogenesis, and T cell differentiation. RUNX3 is also involved in Caspase-3-dependent apoptosis. Protein complexes containing RUNX3 and various transcription factors, such as Smads or β-catenin/TCF4, have tumor suppressor activity and regulate downstream target gene transcription. While typically localized to the nucleus, RUNX3 can be tyrosine phosphorylated and located in the cytoplasm of many cancer cells. This mislocalization of RUNX3 abolishes its tumor suppressor function and contributes to tumorigenesis. |
Other Clones
{{antibodyDetailsPage.numTotal}} Results
-
{{item.title}}
Citations ({{item.publications_count}}) Manual MSDS
Cat.No.：{{item.cat}}
{{index}} {{goods_show_value}}
Other Formats
{{formatDetailsPage.numTotal}} Results
Unconjugated
-
{{item.title}}
Citations ({{item.publications_count}}) Manual MSDS
Cat.No.：{{item.cat}}
{{index}} {{goods_show_value}}
-
IF：{{item.impact}}
Journal：{{item.journal}} ({{item.year}})
DOI：{{item.doi}}Reactivity：{{item.species}}
Sample Type：{{item.organization}}
-
Q{{(FAQpage.currentPage - 1)*pageSize+index+1}}:{{item.name}}
